Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355052 | 0.89 | L3MBTL1 (0.48) | CA9PTGS2CA1CA2CA12 | |
| SCHEMBL6343217 | 0.86 | PTGS2 (0.47) | CA9PTGS2CA1CA2CA12 | |
| SCHEMBL6342797 | 0.86 | PTGS2 (0.48) | CA9PTGS2CA1CA2CA12 | |
| SCHEMBL6353488 | 0.86 | ALDH1A1 (0.48) | CA9PTGS2CA1CA2CA12 | |
| SCHEMBL6342102 | 0.85 | CA2 (0.48) | CA9PTGS2CA1CA2CA12 | |
| SCHEMBL6342790 | 0.84 | PTGS2 (0.50) | CA9PTGS2CA1CA2CA12 | |
| SCHEMBL6344535 | 0.84 | KMT2A (0.54) | CA9PTGS2CA1CA2CA12 | |
| SCHEMBL6343380 | 0.84 | PTGS2 (0.49) | CA9PTGS2CA1CA2CA12 | |
| SCHEMBL6343563 | 0.84 | CA1 (0.49) | CA9PTGS2CA1CA2PTGS1 | |
| SCHEMBL6343697 | 0.83 | PTGS2 (0.46) | CA9PTGS2CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030125361-A1 | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-07-03 | — | — | US | claimed |
| US-6849653-B2 | 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis | PHARMACIA CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125361-A1 | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation | IRAK4, NLRP3, CXCL8 | CA9 2253/4885PTGS2 37/4885CA1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.